New injection targets autoimmune diseases in early trial
Disease control
Recruiting now
This early-phase study tests a new injection called AFN50 in 18 adults with autoimmune diseases like lupus. The main goal is to check safety and side effects, while also looking at how the treatment affects immune cells. Participants must have active disease despite standard trea…
Phase: EARLY_PHASE1 • Sponsor: AlphaNa Bioscience Company Limited • Aim: Disease control
Last updated May 26, 2026 05:24 UTC